Uganda – Inactivated Polio Vaccine (IPV) Support
This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Uganda

2. **Grant Number:** 1518-UGA-25c-X / 15-UGA-08h-Y

3. **Date of Decision Letter:** 15 September 2014

4. **Date of the Partnership Framework Agreement:** 28 June 2013

5. **Programme Title:** NVS, IPV Routine

6. **Vaccine type:** Inactivated Polio Vaccine (IPV)

7. **Requested product presentation and formulation of vaccine**: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID

8. **Programme Duration**: 2015 - 2018

9. **Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):**
   Please note that endorsed or approved amounts for 2017 and 2018 will be communicated in due course, taking into account updated information on country requirements and following GAVI’s review and approval processes.

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
<th>Total³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>$2,485,500</td>
<td>$3,350,000</td>
<td>$5,835,500</td>
</tr>
</tbody>
</table>

10. **Vaccine Introduction Grant:** US$1,356,500

11. **Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):**

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with GAVI funds in each year</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>2,167,100</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>1,430,300</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>15,750</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$2,485,500</td>
</tr>
</tbody>
</table>

12. **Procurement agency:** UNICEF.

13. **Self-procurement:** Not applicable.

---

¹ Please refer to section 18 for additional on IPV presentation.

² This is the entire duration of the programme.

³ This is the total amount endorsed by GAVI for 2015 and 2016.

⁴ This is the amount that GAVI has approved.
14. Co-financing obligations: N/A

GAVI’s usual co-financing requirements do not apply to IPV. However, Uganda is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for campaigns: N/A

16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

<table>
<thead>
<tr>
<th>Reports, documents and other deliverables</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Progress Report or equivalent</td>
<td>To be agreed with GAVI Secretariat</td>
</tr>
</tbody>
</table>

17. Financial Clarifications: The Country shall provide the following clarifications to GAVI:

Not applicable.

Other conditions:
If Uganda envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Uganda.

Signed by,
On behalf of the GAVI Alliance

Hind Khatib-Othman
Managing Director, Country Programmes
15 September 2014